证券代码：300168 证券简称：万达信息 公告编号：2025-023 万达信息股份有限公司 第八届董事会第十五次会议决议公告 二、董事会会议审议情况 （一）审议通过了《关于<2025 年第一季度报告>的议案》。 本议案已经公司第八届董事会审计委员会第十二次会议审议通过，审计委 员会同意将该议案提交公司董事会审议。 董事会认为，《2025 年第一季度报告》能够真实、准确、完整地反映公司 2025 年第一季度的经营情况，同意《2025 年第一季度报告》在中国证监会指定 的信息披露网站披露。 本议案以 9 票同意，0 票反对，0 票弃权获得通过。 《2025 年第一季度报告》同日披露于巨潮资讯网。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 万达信息股份有限公司（以下简称"公司"）第八届董事会第十五次会议于 2025 年 4 月 22 日以邮件方式发出会议通知，于 2025 年 4 月 25 日以通讯表决 方式召开。本次会议由董事长阮琦召集并主持，会议应出席董事 9 人，实际出 席 9 人。本次会议的召集召开符合《公司法》《公司章程》及 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥463,768,748.64, representing a year-on-year increase of 32.61% compared to ¥349,734,530.09 in the same period last year[5]. - The net profit attributable to shareholders was -¥151,861,269.83, an improvement of 28.27% from -¥211,699,810.07 in the previous year[5]. - The net loss for the current period was ¥156,524,166.84, an improvement from a net loss of ¥215,601,850.32 in the previous period, representing a reduction of approximately 27.4%[19]. - The company reported a total comprehensive loss of ¥156,532,317.24, an improvement from a loss of ¥215,591,670.41 in the previous period, reflecting a reduction of approximately 27.4%[19]. - Basic and diluted earnings per share were both reported at -0.1054, an improvement from -0.1469 in the previous period[19]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥400,427,017.99, showing a slight decrease of 3.03% compared to -¥388,642,129.44 in the same period last year[5]. - Cash flow from operating activities showed a net outflow of ¥400,427,017.99, slightly worse than the previous period's outflow of ¥388,642,129.44[21]. - Cash and cash equivalents at the end of the period decreased to ¥719,457,235.93 from ¥1,238,867,142.92 in the previous period, a decline of 41.9%[22]. - Cash flow from financing activities decreased by 101.62% year-on-year, mainly due to increased cash payments for debt repayment[8]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,923,503,153.90, down 6.58% from ¥6,340,914,631.81 at the end of the previous year[5]. - The total assets decreased from CNY 6,340,914,631.81 to CNY 5,923,503,153.90, a reduction of approximately 6.6%[15]. - The total liabilities decreased from CNY 4,734,589,693.47 to CNY 4,473,606,885.41, a reduction of about 5.5%[16]. - The total current liabilities decreased from CNY 3,888,794,149.49 to CNY 3,781,521,830.89, a reduction of approximately 2.7%[16]. - The long-term borrowings decreased from CNY 720,739,800.00 to CNY 576,799,840.00, a reduction of about 20%[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 67,800[10]. - The company's equity attributable to shareholders decreased by 9.24% to ¥1,488,638,611.05 from ¥1,640,219,054.42 at the end of the previous year[5]. - The total equity attributable to the parent company decreased from CNY 1,640,219,054.42 to CNY 1,488,638,611.05, a reduction of about 9.2%[17]. Income and Expenses - Total operating costs increased to ¥579,382,929.23, up 10.6% from ¥523,617,911.73 in the previous period[18]. - The company experienced a 52.34% increase in prepaid accounts compared to the beginning of the year, attributed to project procurement payments not yet settled with suppliers[7]. - The company reported a significant increase in borrowing, with cash received from loans amounting to ¥952,346,140.00, compared to ¥531,840,000.00 in the previous period, marking an increase of 78.9%[22]. - The company incurred a financial expense of ¥13,072,082.96, down from ¥16,749,857.44 in the previous period, indicating a decrease of 22.5%[18]. - Research and development expenses were ¥66,510,264.59, a decrease of 18.4% from ¥81,494,202.14 in the previous period[18]. Investment Income - The company reported a 31.69% decrease in investment income from joint ventures compared to the previous year[8]. - Other income increased by 181.08% year-on-year, primarily due to an increase in government subsidies received[8].

Group 1 - The company, Wanda Information, reported a revenue of 464 million yuan for the first quarter of 2025, representing a year-on-year increase of 32.61% [1] - The net loss for the company in the same period was 152 million yuan, an improvement from a net loss of 212 million yuan in the previous year [1]

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].

Core Insights - The company reported a total revenue of 2.011 billion yuan in 2024, a year-on-year decrease of 18.19% [1] - The net profit attributable to shareholders was -686 million yuan, an increase of 23.70% year-on-year, indicating a narrowing of losses [1] - The company is focusing on three core areas: smart healthcare, smart government, and smart finance, aiming to improve operational efficiency and cost management [6] Financial Performance - In Q4, total revenue was 690 million yuan, a year-on-year increase of 24.7% [2] - The net profit attributable to shareholders in Q4 was -127 million yuan, an increase of 77.41% year-on-year [2] - The gross margin was 19.1%, a decrease of 3.75% year-on-year, while the net margin was -33.89%, an increase of 7.3% year-on-year [8] Cash Flow and Debt Situation - The cash flow situation is concerning, with cash and cash equivalents to current liabilities at only 41.5% [4] - The interest-bearing debt ratio has reached 39.37%, indicating significant risk in cash flow and debt management [4] - The net cash flow from operating activities was -37 million yuan, a decrease of 75.50% year-on-year [8] Revenue Composition - Software development accounted for 970 million yuan, 48.23% of total revenue, with a gross margin of 20.61% [9] - Operations and maintenance generated 627 million yuan, 31.16% of total revenue, with a gross margin of 23.59% [9] - Smart healthcare generated 852 million yuan, 42.34% of total revenue, with a gross margin of 25.45% [9] Future Outlook - The company plans to continue its focus on smart healthcare, smart government, and smart finance, while implementing cost reduction and efficiency measures [6] - There is an emphasis on enhancing marketing capabilities and compliance to ensure stable growth [6]

Core Viewpoint - The company reported a revenue decline of 18.19% to 2.011 billion yuan in 2024, but managed to reduce net losses by 23.70% to 686 million yuan, indicating operational resilience and a focus on core business improvement [1][2]. Group 1: Financial Performance - The company's total revenue for 2024 was 2.011 billion yuan, a decrease of 18.19% year-on-year [1]. - Net loss attributable to shareholders was 686 million yuan, a reduction of 23.70% from the previous year [1]. - Operating cash flow improved significantly, with a net outflow of 37 million yuan, a reduction of 75.50% year-on-year [1]. Group 2: Cost Management and Operational Efficiency - Sales, management, and financial expenses decreased by 14.00%, 15.31%, and 15.79% respectively, showcasing effective cost control [1][2]. - The company achieved positive cash flow in the third and fourth quarters, indicating improved operational efficiency [2]. - The company reported a reduction in asset impairment and credit impairment provisions from 376 million yuan in 2023 to 273 million yuan in 2024, easing financial pressure [3]. Group 3: Strategic Focus and Market Position - The new management strategy emphasizes stability and progress, focusing on core sectors such as smart healthcare, government services, and finance [3]. - The company has seen an increase in revenue contribution from its smart healthcare and smart finance sectors, with smart finance revenue growing by 65.65% year-on-year [3]. - The company maintains a strong domestic market presence, with over 80% of clients being government departments and large enterprises, reducing exposure to international political risks [4]. Group 4: Technological Innovation and Future Growth - The company is leveraging AI and digital transformation to enhance its service offerings and create a competitive edge in the market [5][6]. - In 2024, the company added over 100 new patents and software copyrights, expanding its digital service ecosystem to over 160 million users [6]. - The company aims to focus on cutting-edge technologies such as AI, big data, and cloud computing to drive future growth and improve operational stability [7].

Core Insights - Wanda Information (300168) reported a revenue of 2.011 billion yuan for 2024, a year-on-year decline of 18.19%, while the net profit attributable to shareholders was -6.86 million yuan, an increase of 23.70% year-on-year [1] - The company is focusing on cost reduction and efficiency improvement, with sales, management, and financial expenses decreasing by 14.00%, 15.31%, and 15.79% respectively [1] - The net cash flow from operating activities was -37 million yuan, a reduction in net outflow by 75.50% year-on-year [1] Digital Health Sector - In the digital health sector, the company is deeply involved in healthcare reform, providing health and insurance services to a vast user base across multiple regions [1] - The smart healthcare business is expanding into key areas, maintaining a leading market position, while the smart insurance and pharmaceutical sectors are advancing in market expansion and "AI + insurance" initiatives [1] - The company is developing a multi-level smart solution system for healthcare scenarios through its subsidiaries [1] Digital Government Sector - In the digital government sector, the company leverages its extensive experience and technology to build a city-level "data hub," integrating digital technology with government services and urban governance [2] - This initiative supports the construction of a digital government and creates an efficient ecosystem for data sharing and collaboration [2] Digital Finance Sector - The company has established a smart finance center to expand its business, focusing on six core areas to empower financial institutions [2] - Collaborations with China Life Insurance are underway to implement DRG/DIP systems across multiple locations, promoting high-quality digital development in the finance and insurance sectors [2] Digital Elderly Care Sector - In the digital elderly care sector, the company has built the largest home care cloud (SaaS) platform in the country, covering over 300 care institutions and serving more than 230,000 elderly individuals [2] - The platform has provided over 100 million service instances, showcasing its extensive reach and impact [2] Health Cloud Sector - The health cloud platform, operated by the company's subsidiary, has a wide coverage area and a large user base, achieving significant progress in internet and remote medical services [2] - The services extend to central and western regions, impacting numerous medical institutions and continuously expanding its influence [2] Overall Business Strategy - Wanda Information is recognized as a leading provider of smart city solutions in China, with its business encompassing digital health, digital government, and digital finance sectors [2] - The company is committed to ICT innovation as the foundation for its overall software solutions, extending its development into health cloud, citizen cloud, and other innovative business areas [2]

关于万达信息股份有限公司2024年度 营业收入扣除情况表的鉴证报告 信会师报字[2025]第ZA10832号 万达信息股份有限公司全体股东： 我们审计了万达信息股份有限公司(以下简称"万达信息")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债 表、2024 年度合并及母公司利润表、合并及母公司现金流量表、合并 及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 22 日出具了报告号为信会师报字[2025]第 ZA10828 号的无保留意见 审计报告。 在对上述财务报表执行审计的基础上，我们接受委托，对后附的 万达信息2024年度营业收入扣除情况表（以下简称"营业收入扣除情 况表"）执行了合理保证的鉴证业务。 一、管理层的责任 万达信息管理层的责任是按照《深圳证券交易所创业板股票上市 规则》和《深圳证券交易所创业板上市公司自律监管指南第1号—— 业务办理》的相关规定编制营业收入扣除情况表，确保营业收入扣除 情况表真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 万达信息股份有限公司 营业收入扣除情况表的鉴证报告 2024年度 二、注册会计师的责 ...

万达信息股份有限公司 内部控制审计报告 二 O 二四年度 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是万达信息董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 四、 财务报告内部控制审计意见 内部控制审计报告 信会师报字[2025]第 ZA10829 号 万达信息股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了万达信息股份有限公司（以下简称"万达信息"） 2024 年 12 月 31 日的财务报告内部控制的有效性。 内控审计报告 第 1 页 （此页无正文） 立信会计师事务所 中国注册会计师： ...

万达信息股份有限公司 审计报告及财务报表 二○二四年度 万达信息股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动 | 9-12 | | | 表 | | | | 财务报表附注 | 1-135 | 审 计 报 告 信会师报字[2025]第 ZA10828 号 万达信息股份有限公司全体股东： 一、 审计意见 我们审计了万达信息股份有限公司（以下简称万达信息）财务报 表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所 有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规 ...